{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:15:22Z","timestamp":1781712922846,"version":"3.54.5"},"reference-count":77,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Science Foundation for Africa (SFA) through Grand Challenge Africa","award":["GCA\/DD2\/Round10\/030\/004"],"award-info":[{"award-number":["GCA\/DD2\/Round10\/030\/004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>The emergence and spread of antimalarial drug resistance threaten malaria control efforts in sub-Saharan Africa. Monitoring the susceptibility of circulating Plasmodium falciparum isolates is essential to inform national treatment guidelines and guide the development of new therapies. To assess the ex vivo susceptibility of P. falciparum field isolates to 14 antimalarials, including withdrawn\/unused and currently used drugs, and next-generation agents in Mali.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-six isolates collected from patients with uncomplicated malaria at three endemic sites (Faladje, Kolle and Bougoula-Hameau) were cultured ex vivo under standardized conditions. Parasites were exposed to 14 drugs, including tafenoquine, N-desethyl-amodiaquine, chloroquine, dihydroartemisinin, lumefantrine, pyronaridine, quinine, sulfadoxine, pyrimethamine, amodiaquine, atovaquone, GNF179, KDU691 and cabamiquine. Susceptibility was measured using fluorescence-based assays with SYBR Green I and Mitotracker dyes, and IC50 values were derived from dose\u2013response curves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tafenoquine showed a very low potency (IC50\u200a&amp;gt;\u200a1500\u2005nM). Chloroquine exhibited marked inter- and intra-site variability (IC50 \u223c50\u20131300\u2005nM), while N-desethyl-amodiaquine potently inhibited isolates (median IC50\u200a&amp;lt;\u200a20\u2005nM in Faladje and Bougoula-Hameau). Current frontline drugs, dihydroartemisinin (median IC50\u200a&amp;lt;\u200a6\u2005nM), lumefantrine (median IC50\u200a&amp;lt;\u200a50\u2005nM) and pyronaridine (median IC50\u200a&amp;lt;\u200a10\u2005nM), remained highly potent. Quinine showed variable efficacy (IC50 \u223c75\u20131000\u2005nM). Chemoprevention agents sulfadoxine and pyrimethamine displayed high IC50 values (median IC50\u200a&amp;gt;\u200a1000 and &amp;gt;2000\u2005nM). Atovaquone and amodiaquine consistently inhibited all isolates (IC50\u200a&amp;lt;\u200a10\u2005nM). Next-generation compounds cabamiquine and GNF179 demonstrated consistently strong activity (IC50\u200a&amp;lt;\u200a10\u2005nM), while KDU691 showed moderate activity (median IC50 18\u201322\u2005nM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While current frontline therapies remain effective, reduced activity of chemopreventive antimalarials supports the need for continued surveillance to detect early signs of resistance in Mali. The potent activity of next-generation candidates (cabamiquine and GNF179) supports their potential for further clinical development and field deployment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag015","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:09:00Z","timestamp":1769515740000},"source":"Crossref","is-referenced-by-count":2,"title":["<i>Plasmodium falciparum<\/i>\n                    field isolates drug susceptibility in Mali"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5672-2307","authenticated-orcid":false,"given":"Fatoumata Ousmane","family":"Maiga","sequence":"first","affiliation":[{"name":"University of Sciences, Techniques, and Technologies of Bamako (USTTB), Faculty of Pharmacy, Parasites and Microbes Research and Training Center (P-MRTC) , Point G. PBE: 1805, Bamako ,","place":["Mali"]},{"name":"Pathogens Genomic Diversity Network Africa (PDNA) , Imm. Gwancoura, Sotuba, Bamako ,","place":["Mali"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-8439","authenticated-orcid":false,"given":"Laurent","family":"Dembele","sequence":"additional","affiliation":[{"name":"University of Sciences, Techniques, and Technologies of Bamako (USTTB), Faculty of Pharmacy, Parasites and Microbes Research and Training Center (P-MRTC) , Point G. PBE: 1805, Bamako ,","place":["Mali"]},{"name":"Pathogens Genomic Diversity Network Africa (PDNA) , Imm. Gwancoura, Sotuba, Bamako ,","place":["Mali"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souleymane","family":"Dama","sequence":"additional","affiliation":[{"name":"University of Sciences, Techniques, and Technologies of Bamako (USTTB), Faculty of Pharmacy, Parasites and Microbes Research and Training Center (P-MRTC) , Point G. PBE: 1805, Bamako ,","place":["Mali"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ousmaila","family":"Diakite","sequence":"additional","affiliation":[{"name":"University of Sciences, Techniques, and Technologies of Bamako (USTTB), Faculty of Pharmacy, Parasites and Microbes Research and Training Center (P-MRTC) , Point G. PBE: 1805, Bamako ,","place":["Mali"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatoumata","family":"Diallo","sequence":"additional","affiliation":[{"name":"University of Sciences, Techniques, and Technologies of Bamako (USTTB), Faculty of Pharmacy, Parasites and Microbes Research and Training Center (P-MRTC) , Point G. PBE: 1805, Bamako ,","place":["Mali"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanta","family":"Sogore","sequence":"additional","affiliation":[{"name":"University of Sciences, Techniques, and Technologies of Bamako (USTTB), Faculty of Pharmacy, Parasites and Microbes Research and Training Center (P-MRTC) , Point G. PBE: 1805, Bamako ,","place":["Mali"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Maiga","sequence":"additional","affiliation":[{"name":"University of Sciences, Techniques, and Technologies of Bamako (USTTB), Faculty of Pharmacy, Parasites and Microbes Research and Training Center (P-MRTC) , Point G. PBE: 1805, Bamako ,","place":["Mali"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Dao","sequence":"additional","affiliation":[{"name":"University of Sciences, Techniques, and Technologies of Bamako (USTTB), Faculty of Pharmacy, Parasites and Microbes Research and Training Center (P-MRTC) , Point G. PBE: 1805, Bamako ,","place":["Mali"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niawanlou","family":"Dara","sequence":"additional","affiliation":[{"name":"University of Sciences, Techniques, and Technologies of Bamako (USTTB), Faculty of Pharmacy, Parasites and Microbes Research and Training Center (P-MRTC) , Point G. PBE: 1805, Bamako ,","place":["Mali"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Lamine","family":"Alhousseini","sequence":"additional","affiliation":[{"name":"University of Sciences, Techniques, and Technologies of Bamako (USTTB), Faculty of Pharmacy, Parasites and Microbes Research and Training Center (P-MRTC) , Point G. PBE: 1805, Bamako ,","place":["Mali"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumar Bila","family":"Traore","sequence":"additional","affiliation":[{"name":"University of Sciences, Techniques, and Technologies of Bamako (USTTB), Faculty of Pharmacy, Parasites and Microbes Research and Training Center (P-MRTC) , Point G. PBE: 1805, Bamako ,","place":["Mali"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoulaye A","family":"Djimde","sequence":"additional","affiliation":[{"name":"University of Sciences, Techniques, and Technologies of Bamako (USTTB), Faculty of Pharmacy, Parasites and Microbes Research and Training Center (P-MRTC) , Point G. PBE: 1805, Bamako ,","place":["Mali"]},{"name":"Pathogens Genomic Diversity Network Africa (PDNA) , Imm. Gwancoura, Sotuba, Bamako ,","place":["Mali"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"2026021205530624200_dlag015-B1","author":"World Health Organization"},{"key":"2026021205530624200_dlag015-B2","first-page":"181","volume-title":"Defining and Defeating the Intolerable Burden of Malaria III: Progress and Perspectives: Supplement to Volume 77(6) of American Journal of Tropical Medicine and Hygiene","author":"Nosten","year":"2007"},{"key":"2026021205530624200_dlag015-B3","doi-asserted-by":"publisher","first-page":"a025619","DOI":"10.1101\/cshperspect.a025619","article-title":"Antimalarial drug resistance: a threat to malaria elimination","volume":"7","author":"Menard","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026021205530624200_dlag015-B4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMp1403340","article-title":"The origins of antimalarial-drug resistance","volume":"371","author":"Packard","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021205530624200_dlag015-B5","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/s41564-023-01377-z","article-title":"Chloroquine resistance evolution in Plasmodium falciparum is mediated by the putative amino acid transporter AAT1","volume":"8","author":"Amambua-Ngwa","year":"2023","journal-title":"Nat Microbiol"},{"key":"2026021205530624200_dlag015-B6","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1086\/587845","article-title":"Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from Southwest Uganda","volume":"197","author":"Lynch","year":"2008","journal-title":"J Infect Dis"},{"key":"2026021205530624200_dlag015-B7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1475-2875-8-89","article-title":"A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria","volume":"8","author":"Picot","year":"2009","journal-title":"Malar J"},{"key":"2026021205530624200_dlag015-B8","author":"World Health Organization"},{"key":"2026021205530624200_dlag015-B9","author":"World Health Organization"},{"key":"2026021205530624200_dlag015-B10","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nrmicro2239","article-title":"Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria","volume":"7","author":"Eastman","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"2026021205530624200_dlag015-B11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in Plasmodium falciparum malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N Engl J Med"},{"key":"2026021205530624200_dlag015-B12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","article-title":"A molecular marker of artemisinin-resistant Plasmodium falciparum malaria","volume":"505","author":"Ariey","year":"2014","journal-title":"Nature"},{"key":"2026021205530624200_dlag015-B13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","article-title":"Spread of artemisinin resistance in Plasmodium falciparum malaria","volume":"371","author":"Ashley","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021205530624200_dlag015-B14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1126\/science.1260867","article-title":"Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates","volume":"347","author":"Straimer","year":"2015","journal-title":"Science"},{"key":"2026021205530624200_dlag015-B15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","article-title":"Evidence of artemisinin-resistant malaria in Africa","volume":"385","author":"Balikagala","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021205530624200_dlag015-B16","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","article-title":"Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda","volume":"26","author":"Uwimana","year":"2020","journal-title":"Nat Med"},{"key":"2026021205530624200_dlag015-B17","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/d41591-024-00028-y","article-title":"Urgent action is needed to confront artemisinin partial resistance in African malaria parasites","volume":"30","author":"Ishengoma","year":"2024","journal-title":"Nat Med"},{"key":"2026021205530624200_dlag015-B18","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S1473-3099(13)70252-4","article-title":"Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies","volume":"13","author":"Witkowski","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2026021205530624200_dlag015-B19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1475-2875-6-120","article-title":"World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility","volume":"6","author":"Bacon","year":"2007","journal-title":"Malar J"},{"key":"2026021205530624200_dlag015-B20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12936-015-0769-1","article-title":"Ex vivo anti-malarial drug susceptibility of Plasmodium falciparum isolates from pregnant women in an area of highly seasonal transmission in Burkina Faso","volume":"14","author":"Tahita","year":"2015","journal-title":"Malar J"},{"key":"2026021205530624200_dlag015-B21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/jac\/dkx431","article-title":"Clinical implications of Plasmodium resistance to atovaquone\/proguanil: a systematic review and meta-analysis","volume":"73","author":"Staines","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026021205530624200_dlag015-B22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.4269\/ajtmh.1986.35.711","article-title":"High level of sensitivity to chloroquine of 72 Plasmodium falciparum isolates from Southern Cameroon in January 1985","volume":"35","author":"Brasseur","year":"1986","journal-title":"Am J Trop Med Hyg"},{"key":"2026021205530624200_dlag015-B23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4269\/ajtmh.2000.62.271","article-title":"Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil","volume":"62","author":"Basco","year":"2000","journal-title":"Am J Trop Med Hyg"},{"key":"2026021205530624200_dlag015-B24","doi-asserted-by":"publisher","first-page":"e003217","DOI":"10.1136\/bmjgh-2020-003217","article-title":"Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in Africa: a systematic analysis of national trends","volume":"5","author":"Amimo","year":"2020","journal-title":"BMJ Glob Health"},{"key":"2026021205530624200_dlag015-B25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4269\/ajtmh.1994.50.193","article-title":"In vitro activity of pyrimethamine, cycloguanil, and other antimalarial drugs against African isolates and clones of Plasmodium falciparum","volume":"50","author":"Basco","year":"1994","journal-title":"Am J Trop Med Hyg"},{"key":"2026021205530624200_dlag015-B26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4269\/ajtmh.1993.49.301","article-title":"In vitro activity of artemisinin derivatives against African isolates and clones of Plasmodium falciparum","volume":"49","author":"Basco","year":"1993","journal-title":"Am J Trop Med Hyg"},{"key":"2026021205530624200_dlag015-B27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12936-024-04848-8","article-title":"Emergence of Plasmodium falciparum strains with artemisinin partial resistance in East Africa and the Horn of Africa: is there a need to panic?","volume":"23","author":"Assefa","year":"2024","journal-title":"Malar J"},{"key":"2026021205530624200_dlag015-B28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1475-2875-8-5","article-title":"Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali","volume":"8","author":"Kayentao","year":"2009","journal-title":"Malar J"},{"key":"2026021205530624200_dlag015-B29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4269\/ajtmh.2012.11-0649","article-title":"Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impact","volume":"87","author":"Sagara","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"2026021205530624200_dlag015-B30","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/oxfordjournals.aje.a009179","article-title":"Seasonality and malaria in a West African village: does high parasite density predict fever incidence?","volume":"145","author":"Bouvier","year":"1997","journal-title":"Am J Epidemiol"},{"key":"2026021205530624200_dlag015-B31","doi-asserted-by":"publisher","first-page":"790","DOI":"10.4269\/ajtmh.14-0765","article-title":"Spatial patterns of Plasmodium falciparum clinical incidence, asymptomatic parasite carriage and anopheles density in two villages in Mali","volume":"93","author":"Sissoko","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"2026021205530624200_dlag015-B32","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1093\/jac\/dkab133","article-title":"Plasmodium malariae and Plasmodium falciparum comparative susceptibility to antimalarial drugs in Mali","volume":"76","author":"Dembele","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026021205530624200_dlag015-B33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1574-695X.2009.00641.x","article-title":"A molecular map of chloroquine resistance in Mali","volume":"58","author":"Djimde","year":"2010","journal-title":"FEMS Immunol Med Microbiol"},{"key":"2026021205530624200_dlag015-B34","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1128\/AAC.00777-06","article-title":"In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti","volume":"50","author":"Pradines","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021205530624200_dlag015-B35","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1475-2875-12-450","article-title":"A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs","volume":"12","author":"Quashie","year":"2013","journal-title":"Malar J"},{"key":"2026021205530624200_dlag015-B36","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1086\/367542","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum","volume":"36","author":"Hale","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2026021205530624200_dlag015-B37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12936-017-1862-4","article-title":"The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg)","volume":"16","author":"Dow","year":"2017","journal-title":"Malar J"},{"key":"2026021205530624200_dlag015-B38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4269\/ajtmh.2002.67.39","article-title":"In vitro activity of tafenoquine alone and in combination with artemisinin against Plasmodium falciparum","volume":"67","author":"Ramharter","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"2026021205530624200_dlag015-B39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/ph12030115","article-title":"Tafenoquine: a 2018 novel FDA-approved prodrug for the radical cure of Plasmodium vivax malaria and prophylaxis of malaria","volume":"12","author":"Mayence","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026021205530624200_dlag015-B40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1590\/S0074-02762006000300022","article-title":"Susceptibility of Colombian Plasmodium falciparum isolates to 4-aminoquinolines and the definition of amodiaquine resistance in vitro","volume":"101","author":"Echeverry","year":"2006","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2026021205530624200_dlag015-B41","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/S1473-3099(21)00700-3","article-title":"Chloroquine-resistant Plasmodium falciparum in Pakistan","volume":"21","author":"Khattak","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026021205530624200_dlag015-B42","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1186\/s12936-016-1637-3","article-title":"The return of chloroquine-susceptible Plasmodium falciparum malaria in Zambia","volume":"15","author":"Mwanza","year":"2016","journal-title":"Malar J"},{"key":"2026021205530624200_dlag015-B43","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1086\/375419","article-title":"Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi","volume":"187","author":"Kublin","year":"2003","journal-title":"J Infect Dis"},{"key":"2026021205530624200_dlag015-B44","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4269\/ajtmh.2010.09-0470","article-title":"A non-radioactive DAPI-based high-throughput in vitro assay to assess Plasmodium falciparum responsiveness to antimalarials\u2014increased sensitivity of P. falciparum to chloroquine in Senegal","volume":"82","author":"Ndiaye","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"2026021205530624200_dlag015-B45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/IDR.S295277","article-title":"Ex vivo sensitivity profile of Plasmodium falciparum clinical isolates to a panel of antimalarial drugs in Ghana 13 years after national policy change","volume":"14","author":"Ofori","year":"2021","journal-title":"Infect Drug Resist"},{"key":"2026021205530624200_dlag015-B46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/1475-2875-13-207","article-title":"Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change","volume":"13","author":"Tinto","year":"2014","journal-title":"Malar J"},{"key":"2026021205530624200_dlag015-B47","doi-asserted-by":"publisher","first-page":"1015957","DOI":"10.3389\/fcimb.2022.1015957","article-title":"In vitro susceptibility profile of Plasmodium falciparum clinical isolates from Ghana to antimalarial drugs and polymorphisms in resistance markers","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2026021205530624200_dlag015-B48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12936-017-1700-8","article-title":"Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether\u2013lumefantrine treatment in Mali","volume":"16","author":"Dama","year":"2017","journal-title":"Malar J"},{"key":"2026021205530624200_dlag015-B49","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1038\/ncomms11553","article-title":"Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies","volume":"7","author":"Veiga","year":"2016","journal-title":"Nat Commun"},{"key":"2026021205530624200_dlag015-B50","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4269\/ajtmh.14-0031","article-title":"Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine","volume":"91","author":"Venkatesan","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"2026021205530624200_dlag015-B51","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/infdis\/jis691","article-title":"Quinine treatment selects the pfnhe\u20131 ms4760\u20131 polymorphism in Malian patients with falciparum malaria","volume":"207","author":"Kone","year":"2013","journal-title":"J Infect Dis"},{"key":"2026021205530624200_dlag015-B52","doi-asserted-by":"publisher","first-page":"e0162718","DOI":"10.1371\/journal.pone.0162718","article-title":"Seasonal malaria chemoprevention with sulphadoxine-pyrimethamine and amodiaquine selects Pfdhfr-dhps quintuple mutant genotype in Mali","volume":"11","author":"Maiga","year":"2016","journal-title":"PLoS One"},{"key":"2026021205530624200_dlag015-B53","author":"World Health Organization"},{"key":"2026021205530624200_dlag015-B54","author":"World Health Organization"},{"key":"2026021205530624200_dlag015-B55","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1371\/journal.pctr.0010028","article-title":"A randomized controlled trial of folate supplementation when treating malaria in pregnancy with sulfadoxine-pyrimethamine","volume":"1","author":"Ouma","year":"2006","journal-title":"PLoS Clin Trials"},{"key":"2026021205530624200_dlag015-B56","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/jac\/dkt394","article-title":"Impact of folate supplementation on the efficacy of sulfadoxine\/pyrimethamine in preventing malaria in pregnancy: the potential of 5-methyl-tetrahydrofolate","volume":"69","author":"Nzila","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026021205530624200_dlag015-B57","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1086\/592715","article-title":"Plasma folate level and high-dose folate supplementation predict sulfadoxine-pyrimethamine treatment failure in pregnant women in Western Kenya who have uncomplicated malaria","volume":"198","author":"van Eijk","year":"2008","journal-title":"J Infect Dis"},{"key":"2026021205530624200_dlag015-B58","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4269\/ajtmh.1984.33.325","article-title":"Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro","volume":"33","author":"Chulay","year":"1984","journal-title":"Am J Trop Med Hyg"},{"key":"2026021205530624200_dlag015-B59","doi-asserted-by":"publisher","first-page":"943","DOI":"10.4269\/ajtmh.1999.60.943","article-title":"The antimalarial triazine WR99210 and the prodrug PS-15: folate reversal of in vitro activity against Plasmodium falciparum and a non-antifolate mode of action of the prodrug","volume":"60","author":"Kinyanjui","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"2026021205530624200_dlag015-B60","author":"World Health Organization"},{"key":"2026021205530624200_dlag015-B61","author":"World Health Organization"},{"key":"2026021205530624200_dlag015-B62","author":"World Health Organization"},{"key":"2026021205530624200_dlag015-B63","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1475-2875-7-23","article-title":"In vitro atovaquone\/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand","volume":"7","author":"Khositnithikul","year":"2008","journal-title":"Malar J"},{"key":"2026021205530624200_dlag015-B64","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/jac\/dki420","article-title":"Apparent absence of atovaquone\/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers","volume":"57","author":"Musset","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2026021205530624200_dlag015-B65","doi-asserted-by":"publisher","first-page":"e64299","DOI":"10.1371\/journal.pone.0064299","article-title":"The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008\u20132011","volume":"8","author":"Eyase","year":"2013","journal-title":"PLoS One"},{"key":"2026021205530624200_dlag015-B66","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.4269\/ajtmh.2010.10-0339","article-title":"Association between the pfmdr1 gene and in vitro artemether and lumefantrine sensitivity in Thai isolates of Plasmodium falciparum","volume":"83","author":"Mungthin","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"2026021205530624200_dlag015-B67","doi-asserted-by":"publisher","first-page":"e3001616","DOI":"10.1371\/journal.pbio.3001616","article-title":"Mechanistic basis for multidrug resistance and collateral drug sensitivity conferred to the malaria parasite by polymorphisms in PfMDR1 and PfCRT","volume":"20","author":"Shafik","year":"2022","journal-title":"PLoS Biol"},{"key":"2026021205530624200_dlag015-B68","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1038\/s41467-020-15440-4","article-title":"Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway","volume":"11","author":"LaMonte","year":"2020","journal-title":"Nat Commun"},{"key":"2026021205530624200_dlag015-B69","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1126\/science.1211936","article-title":"Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery","volume":"334","author":"Meister","year":"2011","journal-title":"Science"},{"key":"2026021205530624200_dlag015-B70","doi-asserted-by":"publisher","first-page":"e2407","DOI":"10.1093\/cid\/ciaa952","article-title":"Safety, pharmacokinetics, and causal prophylactic efficacy of KAF156 in a Plasmodium falciparum human infection study","volume":"73","author":"Kublin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026021205530624200_dlag015-B71","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1128\/AAC.03478-14","article-title":"A first-in-human randomized, double-blind, placebo-controlled, single and multiple-ascending oral dose study of novel imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers","volume":"58","author":"Leong","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021205530624200_dlag015-B72","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S1473-3099(23)00209-8","article-title":"Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial","volume":"23","author":"Ogutu","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026021205530624200_dlag015-B73","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1056\/NEJMoa1602250","article-title":"Antimalarial activity of KAF156 in falciparum and Vivax malaria","volume":"375","author":"White","year":"2016","journal-title":"N Engl J Med"},{"key":"2026021205530624200_dlag015-B74","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature12782","article-title":"Targeting Plasmodium phosphatidylinositol 4-kinase to eliminate malaria","volume":"504","author":"McNamara","year":"2013","journal-title":"Nature"},{"key":"2026021205530624200_dlag015-B75","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1128\/AAC.43.2.418","article-title":"In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs","volume":"43","author":"Pradines","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021205530624200_dlag015-B76","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/jac\/42.3.333","article-title":"In-vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents","volume":"42","author":"Pradines","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"2026021205530624200_dlag015-B77","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4269\/ajtmh.2007.76.245","article-title":"In vitro antimalarial drug susceptibility and Pfcrt mutation among fresh Plasmodium falciparum isolates from the Lao PDR (Laos)","volume":"76","author":"Mayxay","year":"2007","journal-title":"Am J Trop Med Hyg"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/1\/dlag015\/66863017\/dlag015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/1\/dlag015\/66863017\/dlag015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:53:12Z","timestamp":1770893592000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag015\/8475161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag015","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,7]]},"article-number":"dlag015"}}